Report Detail
Global Ustekinumab Biosimilars Market 2026 by Manufacturers, Regions, Type and Application, Forecast to 2032
- RnM4752598 |
- 05 October, 2026 |
- Global |
- 99 Pages |
- GIR |
- Pharma & Healthcare
According to our (Global Info Research) latest study, the global Ustekinumab Biosimilars market size was valued at US$ million in 2025 and is forecast to a readjusted size of US$ million by 2032 with a CAGR of %during review period.
Ustekinumab biosimilars are drugs designed to closely replicate the structure and function of ustekinumab,a monoclonal antibody used to treat autoimmune conditions like psoriasis,Crohn's disease,and psoriatic arthritis.
This report is a detailed and comprehensive analysis for global Ustekinumab Biosimilars market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Ustekinumab Biosimilars market size and forecasts, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2021-2032
Global Ustekinumab Biosimilars market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2021-2032
Global Ustekinumab Biosimilars market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2021-2032
Global Ustekinumab Biosimilars market shares of main players, shipments in revenue ($ Million), sales quantity (K Units), and ASP (US$/Unit), 2021-2026
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Ustekinumab Biosimilars
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Ustekinumab Biosimilars market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Teva, Amgen, Samsung Bioepis, Sandoz, Biocon Biologics, Celltrion, Qyuns Therapeutics, Bio-Thera Solutions, Huadong Medicine, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market Segmentation
Ustekinumab Biosimilars market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
Subcutaneous Injection
Intravenous Infusion
Market segment by Application
Crohn's Disease
Ulcerative Colitis
Plaque Psoriasis
Psoriatic Arthritis
Other
Major players covered
Teva
Amgen
Samsung Bioepis
Sandoz
Biocon Biologics
Celltrion
Qyuns Therapeutics
Bio-Thera Solutions
Huadong Medicine
Market segment by region, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Ustekinumab Biosimilars product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Ustekinumab Biosimilars, with price, sales quantity, revenue, and global market share of Ustekinumab Biosimilars from 2021 to 2026.
Chapter 3, the Ustekinumab Biosimilars competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Ustekinumab Biosimilars breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2021 to 2032.
Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2021 to 2032.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2021 to 2026.and Ustekinumab Biosimilars market forecast, by regions, by Type, and by Application, with sales and revenue, from 2027 to 2032.
Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of Ustekinumab Biosimilars.
Chapter 14 and 15, to describe Ustekinumab Biosimilars sales channel, distributors, customers, research findings and conclusion.
1 Market Overview
- 1.1 Product Overview and Scope
- 1.2 Market Estimation Caveats and Base Year
- 1.3 Market Analysis by Type
- 1.3.1 Overview: Global Ustekinumab Biosimilars Consumption Value by Type: 2021 Versus 2025 Versus 2032
- 1.3.2 Subcutaneous Injection
- 1.3.3 Intravenous Infusion
- 1.4 Market Analysis by Application
- 1.4.1 Overview: Global Ustekinumab Biosimilars Consumption Value by Application: 2021 Versus 2025 Versus 2032
- 1.4.2 Crohn's Disease
- 1.4.3 Ulcerative Colitis
- 1.4.4 Plaque Psoriasis
- 1.4.5 Psoriatic Arthritis
- 1.4.6 Other
- 1.5 Global Ustekinumab Biosimilars Market Size & Forecast
- 1.5.1 Global Ustekinumab Biosimilars Consumption Value (2021 & 2025 & 2032)
- 1.5.2 Global Ustekinumab Biosimilars Sales Quantity (2021-2032)
- 1.5.3 Global Ustekinumab Biosimilars Average Price (2021-2032)
2 Manufacturers Profiles
- 2.1 Teva
- 2.1.1 Teva Details
- 2.1.2 Teva Major Business
- 2.1.3 Teva Ustekinumab Biosimilars Product and Services
- 2.1.4 Teva Ustekinumab Biosimilars Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
- 2.1.5 Teva Recent Developments/Updates
- 2.2 Amgen
- 2.2.1 Amgen Details
- 2.2.2 Amgen Major Business
- 2.2.3 Amgen Ustekinumab Biosimilars Product and Services
- 2.2.4 Amgen Ustekinumab Biosimilars Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
- 2.2.5 Amgen Recent Developments/Updates
- 2.3 Samsung Bioepis
- 2.3.1 Samsung Bioepis Details
- 2.3.2 Samsung Bioepis Major Business
- 2.3.3 Samsung Bioepis Ustekinumab Biosimilars Product and Services
- 2.3.4 Samsung Bioepis Ustekinumab Biosimilars Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
- 2.3.5 Samsung Bioepis Recent Developments/Updates
- 2.4 Sandoz
- 2.4.1 Sandoz Details
- 2.4.2 Sandoz Major Business
- 2.4.3 Sandoz Ustekinumab Biosimilars Product and Services
- 2.4.4 Sandoz Ustekinumab Biosimilars Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
- 2.4.5 Sandoz Recent Developments/Updates
- 2.5 Biocon Biologics
- 2.5.1 Biocon Biologics Details
- 2.5.2 Biocon Biologics Major Business
- 2.5.3 Biocon Biologics Ustekinumab Biosimilars Product and Services
- 2.5.4 Biocon Biologics Ustekinumab Biosimilars Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
- 2.5.5 Biocon Biologics Recent Developments/Updates
- 2.6 Celltrion
- 2.6.1 Celltrion Details
- 2.6.2 Celltrion Major Business
- 2.6.3 Celltrion Ustekinumab Biosimilars Product and Services
- 2.6.4 Celltrion Ustekinumab Biosimilars Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
- 2.6.5 Celltrion Recent Developments/Updates
- 2.7 Qyuns Therapeutics
- 2.7.1 Qyuns Therapeutics Details
- 2.7.2 Qyuns Therapeutics Major Business
- 2.7.3 Qyuns Therapeutics Ustekinumab Biosimilars Product and Services
- 2.7.4 Qyuns Therapeutics Ustekinumab Biosimilars Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
- 2.7.5 Qyuns Therapeutics Recent Developments/Updates
- 2.8 Bio-Thera Solutions
- 2.8.1 Bio-Thera Solutions Details
- 2.8.2 Bio-Thera Solutions Major Business
- 2.8.3 Bio-Thera Solutions Ustekinumab Biosimilars Product and Services
- 2.8.4 Bio-Thera Solutions Ustekinumab Biosimilars Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
- 2.8.5 Bio-Thera Solutions Recent Developments/Updates
- 2.9 Huadong Medicine
- 2.9.1 Huadong Medicine Details
- 2.9.2 Huadong Medicine Major Business
- 2.9.3 Huadong Medicine Ustekinumab Biosimilars Product and Services
- 2.9.4 Huadong Medicine Ustekinumab Biosimilars Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
- 2.9.5 Huadong Medicine Recent Developments/Updates
3 Competitive Environment: Ustekinumab Biosimilars by Manufacturer
- 3.1 Global Ustekinumab Biosimilars Sales Quantity by Manufacturer (2021-2026)
- 3.2 Global Ustekinumab Biosimilars Revenue by Manufacturer (2021-2026)
- 3.3 Global Ustekinumab Biosimilars Average Price by Manufacturer (2021-2026)
- 3.4 Market Share Analysis (2025)
- 3.4.1 Producer Shipments of Ustekinumab Biosimilars by Manufacturer Revenue ($MM) and Market Share (%): 2025
- 3.4.2 Top 3 Ustekinumab Biosimilars Manufacturer Market Share in 2025
- 3.4.3 Top 6 Ustekinumab Biosimilars Manufacturer Market Share in 2025
- 3.5 Ustekinumab Biosimilars Market: Overall Company Footprint Analysis
- 3.5.1 Ustekinumab Biosimilars Market: Region Footprint
- 3.5.2 Ustekinumab Biosimilars Market: Company Product Type Footprint
- 3.5.3 Ustekinumab Biosimilars Market: Company Product Application Footprint
- 3.6 New Market Entrants and Barriers to Market Entry
- 3.7 Mergers, Acquisition, Agreements, and Collaborations
4 Consumption Analysis by Region
- 4.1 Global Ustekinumab Biosimilars Market Size by Region
- 4.1.1 Global Ustekinumab Biosimilars Sales Quantity by Region (2021-2032)
- 4.1.2 Global Ustekinumab Biosimilars Consumption Value by Region (2021-2032)
- 4.1.3 Global Ustekinumab Biosimilars Average Price by Region (2021-2032)
- 4.2 North America Ustekinumab Biosimilars Consumption Value (2021-2032)
- 4.3 Europe Ustekinumab Biosimilars Consumption Value (2021-2032)
- 4.4 Asia-Pacific Ustekinumab Biosimilars Consumption Value (2021-2032)
- 4.5 South America Ustekinumab Biosimilars Consumption Value (2021-2032)
- 4.6 Middle East & Africa Ustekinumab Biosimilars Consumption Value (2021-2032)
5 Market Segment by Type
- 5.1 Global Ustekinumab Biosimilars Sales Quantity by Type (2021-2032)
- 5.2 Global Ustekinumab Biosimilars Consumption Value by Type (2021-2032)
- 5.3 Global Ustekinumab Biosimilars Average Price by Type (2021-2032)
6 Market Segment by Application
- 6.1 Global Ustekinumab Biosimilars Sales Quantity by Application (2021-2032)
- 6.2 Global Ustekinumab Biosimilars Consumption Value by Application (2021-2032)
- 6.3 Global Ustekinumab Biosimilars Average Price by Application (2021-2032)
7 North America
- 7.1 North America Ustekinumab Biosimilars Sales Quantity by Type (2021-2032)
- 7.2 North America Ustekinumab Biosimilars Sales Quantity by Application (2021-2032)
- 7.3 North America Ustekinumab Biosimilars Market Size by Country
- 7.3.1 North America Ustekinumab Biosimilars Sales Quantity by Country (2021-2032)
- 7.3.2 North America Ustekinumab Biosimilars Consumption Value by Country (2021-2032)
- 7.3.3 United States Market Size and Forecast (2021-2032)
- 7.3.4 Canada Market Size and Forecast (2021-2032)
- 7.3.5 Mexico Market Size and Forecast (2021-2032)
8 Europe
- 8.1 Europe Ustekinumab Biosimilars Sales Quantity by Type (2021-2032)
- 8.2 Europe Ustekinumab Biosimilars Sales Quantity by Application (2021-2032)
- 8.3 Europe Ustekinumab Biosimilars Market Size by Country
- 8.3.1 Europe Ustekinumab Biosimilars Sales Quantity by Country (2021-2032)
- 8.3.2 Europe Ustekinumab Biosimilars Consumption Value by Country (2021-2032)
- 8.3.3 Germany Market Size and Forecast (2021-2032)
- 8.3.4 France Market Size and Forecast (2021-2032)
- 8.3.5 United Kingdom Market Size and Forecast (2021-2032)
- 8.3.6 Russia Market Size and Forecast (2021-2032)
- 8.3.7 Italy Market Size and Forecast (2021-2032)
9 Asia-Pacific
- 9.1 Asia-Pacific Ustekinumab Biosimilars Sales Quantity by Type (2021-2032)
- 9.2 Asia-Pacific Ustekinumab Biosimilars Sales Quantity by Application (2021-2032)
- 9.3 Asia-Pacific Ustekinumab Biosimilars Market Size by Region
- 9.3.1 Asia-Pacific Ustekinumab Biosimilars Sales Quantity by Region (2021-2032)
- 9.3.2 Asia-Pacific Ustekinumab Biosimilars Consumption Value by Region (2021-2032)
- 9.3.3 China Market Size and Forecast (2021-2032)
- 9.3.4 Japan Market Size and Forecast (2021-2032)
- 9.3.5 South Korea Market Size and Forecast (2021-2032)
- 9.3.6 India Market Size and Forecast (2021-2032)
- 9.3.7 Southeast Asia Market Size and Forecast (2021-2032)
- 9.3.8 Australia Market Size and Forecast (2021-2032)
10 South America
- 10.1 South America Ustekinumab Biosimilars Sales Quantity by Type (2021-2032)
- 10.2 South America Ustekinumab Biosimilars Sales Quantity by Application (2021-2032)
- 10.3 South America Ustekinumab Biosimilars Market Size by Country
- 10.3.1 South America Ustekinumab Biosimilars Sales Quantity by Country (2021-2032)
- 10.3.2 South America Ustekinumab Biosimilars Consumption Value by Country (2021-2032)
- 10.3.3 Brazil Market Size and Forecast (2021-2032)
- 10.3.4 Argentina Market Size and Forecast (2021-2032)
11 Middle East & Africa
- 11.1 Middle East & Africa Ustekinumab Biosimilars Sales Quantity by Type (2021-2032)
- 11.2 Middle East & Africa Ustekinumab Biosimilars Sales Quantity by Application (2021-2032)
- 11.3 Middle East & Africa Ustekinumab Biosimilars Market Size by Country
- 11.3.1 Middle East & Africa Ustekinumab Biosimilars Sales Quantity by Country (2021-2032)
- 11.3.2 Middle East & Africa Ustekinumab Biosimilars Consumption Value by Country (2021-2032)
- 11.3.3 Turkey Market Size and Forecast (2021-2032)
- 11.3.4 Egypt Market Size and Forecast (2021-2032)
- 11.3.5 Saudi Arabia Market Size and Forecast (2021-2032)
- 11.3.6 South Africa Market Size and Forecast (2021-2032)
12 Market Dynamics
- 12.1 Ustekinumab Biosimilars Market Drivers
- 12.2 Ustekinumab Biosimilars Market Restraints
- 12.3 Ustekinumab Biosimilars Trends Analysis
- 12.4 Porters Five Forces Analysis
- 12.4.1 Threat of New Entrants
- 12.4.2 Bargaining Power of Suppliers
- 12.4.3 Bargaining Power of Buyers
- 12.4.4 Threat of Substitutes
- 12.4.5 Competitive Rivalry
13 Raw Material and Industry Chain
- 13.1 Raw Material of Ustekinumab Biosimilars and Key Manufacturers
- 13.2 Manufacturing Costs Percentage of Ustekinumab Biosimilars
- 13.3 Ustekinumab Biosimilars Production Process
- 13.4 Industry Value Chain Analysis
14 Shipments by Distribution Channel
- 14.1 Sales Channel
- 14.1.1 Direct to End-User
- 14.1.2 Distributors
- 14.2 Ustekinumab Biosimilars Typical Distributors
- 14.3 Ustekinumab Biosimilars Typical Customers
15 Research Findings and Conclusion
16 Appendix
- 16.1 Methodology
- 16.2 Research Process and Data Source
Summary:
Get latest Market Research Reports on Ustekinumab Biosimilars. Industry analysis & Market Report on Ustekinumab Biosimilars is a syndicated market report, published as Global Ustekinumab Biosimilars Market 2026 by Manufacturers, Regions, Type and Application, Forecast to 2032. It is complete Research Study and Industry Analysis of Ustekinumab Biosimilars market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.
REPORT YOU MIGHT BE INTERESTED
Related Reports
Reason to Buy
Reports and Markets
Contact Us
+1-352-353-0818 (US)Newsletter
KEEP UP TO DATE ON ALL THE LATEST REPORTS
